Integrated Research Limited ((AU:IRI)) has held its Q2 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integrated Research’s latest earnings call painted a balanced yet uneasy picture for investors. Management acknowledged that a sizable one-off credit loss and ongoing churn in key product lines pushed earnings into the red and trimmed underlying revenue. Yet they also stressed a debt-free balance sheet, stronger cash generation and visible progress on an ambitious product-led growth strategy built around new AI offerings.
Revenue Slips as Underlying Trends Weaken
Statutory revenue for the first half of FY26 came in at $28.3 million, down 2% from the prior corresponding period, signaling modest top-line pressure. On a pro forma basis, which smooths license timing, revenue fell 6% to $34.4 million, reflecting a 4% decline in term-based contracts and a 2% drop in services income.
AI-Driven Product Launches and Roadmap
Management highlighted the launch of Iris, an AI-powered natural-language observability interface, and Elevate, a Prognosis-as-a-service offering, as key milestones in H1. Looking ahead, IR Labs is developing a standalone AI MVP targeted for calendar 2026 and plans Iris expansion into Transact and Infrastructure by the end of FY26, including advanced agentic and data-layer capabilities.
Strategic U.S. Bank Deployment as Reference Win
A notable bright spot was the full implementation of IR’s High Value Payments solution at a top-10 U.S. bank, described as a foundational deployment. Management said this flagship reference is already encouraging new discussions with other global institutions, positioning the payments platform as a cornerstone for future enterprise wins.
New Clients and Expansion Gain Traction
While not yet transformational, new client revenue grew modestly with a cluster of strong late-period wins, particularly in Government, Health and Defence. Expansion activity through cross-sell and upsell delivered a strong percentage uplift off a low base, suggesting existing customers are starting to adopt more of the portfolio.
Transact Emerges as Product-Line Winner
Within the product mix, Transact was the clear outperformer, with pro forma revenue up 6%, largely driven by expansion bookings. This contrasted with declines across other product lines and underlined Transact’s growing strategic importance as a driver of future growth.
Cash and Liquidity Strengthen Despite Loss
IR exited the half with cash of $43.6 million, up 8%, underscoring solid liquidity even as profit slipped. Operating cash flow improved sharply to $5.5 million from $0.5 million a year earlier, and with no debt on the balance sheet, the company emphasized ample flexibility to fund its product agenda.
Cost Discipline Supports Strategic Reinvestment
Operating expenses excluding the expected credit loss fell 4% to $26.5 million, signaling continued cost discipline in the core business. Sales and Marketing spend dropped 9%, while Product and Technology investment rose 14%, reflecting a deliberate pivot toward innovation over near-term sales push.
Balance Sheet Remains a Key Safety Net
Net assets stood at $95.7 million, down 5% year on year but still described as strong, giving IR capital headroom for product-led growth initiatives. Management also noted that net tangible assets per share declined 7% to $0.53, capturing some of the balance sheet impact from weak earnings.
Credit Loss Drives Swing to Loss-Making
A $4.8 million expected credit loss, largely tied to a single reseller, was booked in general and administrative expenses and proved pivotal for the bottom line. This charge flipped operating EBITDA to a $3.1 million loss and net after-tax to a $1.5 million loss, a sharp reversal from profits of $4.6 million on both measures in the prior period.
Core Product and Pro Forma Declines
Overall pro forma revenue fell 6%, with Collaborate, the largest product, down 9%, around 5% of which stemmed from lower testing and services following the sale of the testing business. Infrastructure revenue also fell 9%, with both declines attributed mainly to customer churn, underscoring pressure in legacy lines.
Soft Renewals Add to Revenue Volatility
Renewals were slightly weaker than a year ago and contributed less to total revenue, highlighting a softer renewal book. Management acknowledged that reliance on renewals continues to inject volatility into the top line, complicating visibility while the company shifts toward a product-led growth model.
Margin Pressure and Profitability Outlook
EBITDA turning to a $3.1 million loss underlined the current earnings squeeze and the fragile margin profile. Management cautioned that expenses will rise further in the second half as the company accelerates its growth investments, meaning profitability is likely to remain under pressure in the near term.
Services Drag from Testing Business Sale
The earlier sale of IR’s testing business distorted year-on-year comparisons and weighed on services revenue in H1. This one-off structural change not only dragged on Collaborate and services figures but also reduced the non-recurring revenue that had previously helped cushion results.
Lower Other Gains Remove Cushion
Other gains and losses were a small $0.1 million loss, including $1.1 million of currency losses, compared with a $3.3 million gain a year earlier. The prior period had been boosted by gains from the testing business sale, so the absence of those non-operating benefits removed an earnings buffer this half.
Subscription Revenues Yet to Reignite
Subscription fees were flat to down around 3% compared with the prior period, underlining that the transition to consumption and subscription-based growth has yet to gain real traction. This sluggish performance leaves more of the heavy lifting to new product launches and expansion in coming periods.
Guidance and Investment Plans Tilt to Growth
Management noted that H1 FY26 results landed at the upper end of guidance, even as they reflected a 2% statutory and 6% pro forma revenue decline with earnings hit by the $4.8 million credit loss. For H2, the company signaled higher operating expenses to accelerate its product-led strategy, including Iris rollouts to Transact and Infrastructure by late FY26 and an IR Labs AI MVP in calendar 2026, while expecting subscription fees to remain flat to slightly down and relying on its $43.6 million cash and strong net assets as funding headroom.
The call left investors weighing near-term pain against long-term promise, with earnings, renewals and churn clearly under strain while AI-driven launches and a robust balance sheet offer upside potential. Integrated Research is betting that increased investment now will reignite growth in FY26 and beyond, but markets will be watching closely for improving subscription momentum, stabilizing renewals and evidence that new products can offset legacy declines.